Tag Archives: OMER

Omeros (OMER) Received its Third Buy in a Row

After H.C. Wainwright and Cantor Fitzgerald gave Omeros (NASDAQ: OMER) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Omeros today and set a price target

Tuesday’s Midday Movers: Omeros (OMER), Zogenix (ZGNX), Cytokinetics (CYTK), Karyopharm Therapeutics (KPTI), Invivo Therapeutics Holdings (NVIV)

So far Tuesday, March 3, NASDAQ is down -2.41% and the S&P is down -3.08%. Here are this morning’s most active stocks: Omeros (OMER – Research Report), Zogenix (ZGNX – Research Report), Cytokinetics (CYTK – Research Report), Karyopharm Therapeutics (KPTI

Thursday’s Highlights at Noon: Goodrich Petroleum (GDP), Rite Aid (RAD), Aerie Pharma (AERI), Omeros (OMER), Amarin (AMRN)

So far Thursday, December 19, NASDAQ is up 1.09% and the S&P is up 0.89%. Here are this morning’s most active stocks: Goodrich Petroleum (GDP – Research Report), Rite Aid (RAD – Research Report), Aerie Pharma (AERI – Research Report),

A Director at Omeros is Exercising Options

Yesterday it was reported that a Director at Omeros (OMER – Research Report), Leroy Phd Hood, exercised options to buy 10,000 OMER shares at $7.56 a share, for a total transaction value of $75.6K. The options were close to expired

Maxim Group Sticks to Its Buy Rating for Omeros (OMER)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Omeros (OMER – Research Report) yesterday and set a price target of $25.00. The company’s shares closed last Monday at $13.24. According to TipRanks.com, McCarthy has 0 stars on 0-5

Needham Maintains a Hold Rating on Omeros (OMER)

Needham analyst Serge Belanger maintained a Hold rating on Omeros (OMER – Research Report) today. The company’s shares closed last Monday at $15.21. According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.9% and a 44.9%